Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT00507442
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- T Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00501826
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
- Conditions
- Choroidal NeovascularizationMacular Degeneration
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT00492284
- Locations
- 🇺🇸
Retina Centers, PC, Tucson, Arizona, United States
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
- Conditions
- Colorectal CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00492999
- Locations
- 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT00491127
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Dexamethasone for Symptom Burden in Advanced Cancer Patients
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 132
- Registration Number
- NCT00489307
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson Hospital, Houston, Texas, United States
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 150
- Registration Number
- NCT00482261
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00479089
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT00478777
- Locations
- 🇩🇪
Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪EPS - Early Phase Solutions GmbH, Jena, Germany
🇩🇪Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen, Essen, Germany
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: filgrastimDrug: dexamethasoneDrug: melphalanProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 89
- Registration Number
- NCT00477971
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.